SYDNEY, AUSTRALIA--(Marketwired - Jan 30, 2014) - Prima BioMed Ltd (
The Company's presentation is scheduled to begin at 10:30am Eastern US Time and will be available via a live audio webcast. To access the webcast, please go to http://www.veracast.com/webcasts/bio/ceoinvestor2014/93126297249.cfm. A replay of the webcast will be available for 90 days following the presentation and may be accessed by visiting Prima BioMed's website.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
Contact Information:
For further information please contact:
USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52